Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Medgate Extends European ResAppDx Trial

06/02/2021 | 06:40pm EDT

ResApp Health Limited provided an update on Medgate AG's ("Medgate") pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services. Medgate commenced a pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services in March 2021. Following an interim review, Medgate and ResApp have decided to extend the pilot by two months. This additional time will be used to collect further data and optimise Medgate's integration of ResAppDx within its telemedicine services.


ę S&P Capital IQ 2021
All news about RESAPP HEALTH LIMITED
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
CI
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
PU
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
CI
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,92 M -4,92 M
Net cash 2021 6,40 M 4,64 M 4,64 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 64,4 M 46,7 M 46,8 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-11.76%47
SNAP INC.65.99%132 215
ANGI INC.9.13%7 260
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-45.73%4 958
CONTEXTLOGIC INC.-67.00%3 781